Daesang Accelerates Expansion of Its Allulose Business with Sweevero

Daesang reported that North American allulose sales rose 450% year over year in 2025, with its customer network reaching approximately 30 companies since entering the market in 2023. The company is expanding its Sweevero customized sugar-reduction solutions, supported by a dedicated South Korean production facility established after an approximately KRW 30 billion investment in 2023. Daesang plans to pursue additional global markets and is exploring greater production capacity and a more regionally diversified supply network.

Analysis

The commercial signal is more meaningful as evidence of repeat customer qualification than as proof of material earnings: a roughly 30-company network suggests formulation trials are converting into some adoption, but 450% growth off an undisclosed base says little about revenue scale, utilization, or contribution margin. The key value driver is whether Daesang can turn ingredient sales into higher-retention formulation support; customized blends and taste work could deepen customer switching costs, while also increasing service and development costs.

Near term, treat this as a company-promotional data point, not an earnings catalyst. Over 1–3 months, verify absolute North American sales, repeat-order rates, capacity utilization, pricing, and any segment-level disclosure before underwriting financial impact. Over 6–18 months, expansion into other regions could broaden the market, but local production may require capital and the regulatory treatment of allulose varies by jurisdiction; export growth is not automatic.

Potential beneficiaries include specialized ingredient suppliers and food manufacturers able to reformulate products without sacrificing taste. Conversely, established sweetener portfolios from Ingredion, Tate & Lyle, and Cargill may face competitive pressure if allulose gains share, though the article does not establish direct displacement or Daesang’s cost advantage. The contrarian point: demand tailwinds may be real, but rapid percentage growth and customer counts can mask a small, low-margin business; supply reliability, realized economics, and regulatory access matter more than the headline growth rate.

Key Decisions for Investors

• No immediate directional equity trade: the supplied data has no ticker mapping, and the release omits absolute sales, profitability, and capacity utilization. Do not infer consolidated Daesang earnings materiality from the growth rate.
• Set a 1–3 month diligence trigger for Daesang disclosures or customer/industry checks on absolute allulose revenue, repeat orders, price realization, utilization, and production cost. Upgrade the thesis only if adoption translates into measurable margins or guidance.
• Watch Ingredion, Tate & Lyle, and Cargill as potential competitive exposures, not automatic shorts: evidence of reformulations switching from their products, customer wins/losses, or pricing pressure would be needed to establish a trade.
• Falsifiers: North American sales growth stalls, repeat orders fail to follow initial customer additions, capacity expansion depresses returns, or regulatory barriers constrain entry into targeted markets. Evidence of durable repeat demand and attractive unit economics would instead strengthen the structural case.